Acupuncture anesthesia

Gene symbol: CD3E

Also known as: T3E; TCRE; IMD18; CD3epsilon

Organism: Homo sapiens

Summary: The protein encoded by this gene is the CD3-epsilon polypeptide, which together with CD3-gamma, -delta and -zeta, and the T-cell receptor alpha/beta and gamma/delta heterodimers, forms the T-cell receptor-CD3 complex. This complex plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. The genes encoding the epsilon, gamma and delta polypeptides are located in the same cluster on chromosome 11. The epsilon polypeptide plays an essential role in T-cell development. Defects in this gene cause immunodeficiency. This gene has also been linked to a susceptibility to type I diabetes in women. [provided by RefSeq, Jul 2008]

NCBI gene ID: 916 Ensembl:ENSG00000198851 MIM:186830 AllianceGenome:HGNC:1674

GO Annotation

Category	Term ID	Term description
Process	GO:0001775	Cell activation
Process	GO:0001817	Regulation of cytokine production
Process	GO:0001819	Positive regulation of cytokine production
Process	GO:0001932	Regulation of protein phosphorylation
Process	GO:0001934	Positive regulation of protein phosphorylation
Process	GO:0001952	Regulation of cell-matrix adhesion
Process	GO:0001954	Positive regulation of cell-matrix adhesion
Process	GO:0002249	Lymphocyte anergy
Process	GO:0002250	Adaptive immune response
Process	GO:0002253	Activation of immune response
Process	GO:0002376	Immune system process
Process	GO:0002429	Immune response-activating cell surface receptor signaling pathway
Process	GO:0002507	Tolerance induction
Process	GO:0002517	T cell tolerance induction
Process	GO:0002520	Immune system development
Process	GO:0002521	Leukocyte differentiation
Process	GO:0002643	Regulation of tolerance induction
Process	GO:0002645	Positive regulation of tolerance induction
Process	GO:0002664	Regulation of T cell tolerance induction
Process	GO:0002666	Positive regulation of T cell tolerance induction
Process	GO:0002667	Regulation of T cell anergy
Process	GO:0002669	Positive regulation of T cell anergy
Process	GO:0002682	Regulation of immune system process
Process	GO:0002684	Positive regulation of immune system process
Process	GO:0002694	Regulation of leukocyte activation
Process	GO:0002696	Positive regulation of leukocyte activation
Process	GO:0002757	Immune response-activating signal transduction
Process	GO:0002764	Immune response-regulating signaling pathway
Process	GO:0002768	Immune response-regulating cell surface receptor signaling pathway
Process	GO:0002870	T cell anergy
Process	GO:0002911	Regulation of lymphocyte anergy
Process	GO:0002913	Positive regulation of lymphocyte anergy
Process	GO:0006468	Protein phosphorylation
Process	GO:0006793	Phosphorus metabolic process
Process	GO:0006796	Phosphate-containing compound metabolic process
Process	GO:0006807	Nitrogen compound metabolic process
Process	GO:0006915	Apoptotic process
Process	GO:0006955	Immune response
Process	GO:0007154	Cell communication
Process	GO:0007165	Signal transduction
Process	GO:0007166	Cell surface receptor signaling pathway
Process	GO:0007167	Enzyme-linked receptor protein signaling pathway
Process	GO:0007169	Transmembrane receptor protein tyrosine kinase signaling pathway
Process	GO:0007172	Signal complex assembly
Process	GO:0007186	G protein-coupled receptor signaling pathway
Process	GO:0007224	Smoothened signaling pathway
Process	GO:0007275	Multicellular organism development
Process	GO:0007399	Nervous system development
Process	GO:0007417	Central nervous system development
Process	GO:0007420	Brain development
Process	GO:0008152	Metabolic process
Process	GO:0008219	Cell death
Process	GO:0008283	Cell population proliferation
Process	GO:0008284	Positive regulation of cell population proliferation
Process	GO:0008589	Regulation of smoothened signaling pathway
Process	GO:0009892	Negative regulation of metabolic process
Process	GO:0009893	Positive regulation of metabolic process
Process	GO:0009966	Regulation of signal transduction
Process	GO:0009967	Positive regulation of signal transduction
Process	GO:0009968	Negative regulation of signal transduction
Process	GO:0009987	Cellular process
Process	GO:0010468	Regulation of gene expression
Process	GO:0010562	Positive regulation of phosphorus metabolic process
Process	GO:0010604	Positive regulation of macromolecule metabolic process
Process	GO:0010605	Negative regulation of macromolecule metabolic process
Process	GO:0010628	Positive regulation of gene expression
Process	GO:0010629	Negative regulation of gene expression
Process	GO:0010646	Regulation of cell communication
Process	GO:0010647	Positive regulation of cell communication
Process	GO:0010648	Negative regulation of cell communication
Process	GO:0010810	Regulation of cell-substrate adhesion
Process	GO:0010811	Positive regulation of cell-substrate adhesion
Process	GO:0010941	Regulation of cell death
Process	GO:0012501	Programmed cell death
Process	GO:0016043	Cellular component organization
Process	GO:0016310	Phosphorylation
Process	GO:0016358	Dendrite development
Process	GO:0018108	Peptidyl-tyrosine phosphorylation
Process	GO:0018193	Peptidyl-amino acid modification
Process	GO:0018212	Peptidyl-tyrosine modification
Process	GO:0019220	Regulation of phosphate metabolic process
Process	GO:0019222	Regulation of metabolic process
Process	GO:0019538	Protein metabolic process
Process	GO:0019722	Calcium-mediated signaling
Process	GO:0019932	Second-messenger-mediated signaling
Process	GO:0021549	Cerebellum development
Process	GO:0022008	Neurogenesis
Process	GO:0022037	Metencephalon development
Process	GO:0022407	Regulation of cell-cell adhesion
Process	GO:0022409	Positive regulation of cell-cell adhesion
Process	GO:0022607	Cellular component assembly
Process	GO:0023051	Regulation of signaling
Process	GO:0023052	Signaling
Process	GO:0023056	Positive regulation of signaling
Process	GO:0023057	Negative regulation of signaling
Process	GO:0030030	Cell projection organization
Process	GO:0030097	Hemopoiesis
Process	GO:0030098	Lymphocyte differentiation
Process	GO:0030154	Cell differentiation
Process	GO:0030155	Regulation of cell adhesion
Process	GO:0030182	Neuron differentiation
Process	GO:0030217	T cell differentiation
Process	GO:0030902	Hindbrain development
Process	GO:0031175	Neuron projection development
Process	GO:0031294	Lymphocyte costimulation
Process	GO:0031295	T cell costimulation
Process	GO:0031323	Regulation of cellular metabolic process
Process	GO:0031325	Positive regulation of cellular metabolic process
Process	GO:0031399	Regulation of protein modification process
Process	GO:0031401	Positive regulation of protein modification process
Process	GO:0032501	Multicellular organismal process
Process	GO:0032502	Developmental process
Process	GO:0032649	Regulation of interferon-gamma production
Process	GO:0032663	Regulation of interleukin-2 production
Process	GO:0032673	Regulation of interleukin-4 production
Process	GO:0032729	Positive regulation of interferon-gamma production
Process	GO:0032743	Positive regulation of interleukin-2 production
Process	GO:0032753	Positive regulation of interleukin-4 production
Process	GO:0032943	Mononuclear cell proliferation
Process	GO:0032944	Regulation of mononuclear cell proliferation
Process	GO:0032946	Positive regulation of mononuclear cell proliferation
Process	GO:0033077	T cell differentiation in thymus
Process	GO:0033628	Regulation of cell adhesion mediated by integrin
Process	GO:0033630	Positive regulation of cell adhesion mediated by integrin
Process	GO:0033632	Regulation of cell-cell adhesion mediated by integrin
Process	GO:0033634	Positive regulation of cell-cell adhesion mediated by integrin
Process	GO:0035556	Intracellular signal transduction
Process	GO:0035710	CD4-positive, alpha-beta T cell activation
Process	GO:0035739	CD4-positive, alpha-beta T cell proliferation
Process	GO:0036211	Protein modification process
Process	GO:0042098	T cell proliferation
Process	GO:0042102	Positive regulation of T cell proliferation
Process	GO:0042110	T cell activation
Process	GO:0042127	Regulation of cell population proliferation
Process	GO:0042129	Regulation of T cell proliferation
Process	GO:0042325	Regulation of phosphorylation
Process	GO:0042327	Positive regulation of phosphorylation
Process	GO:0042981	Regulation of apoptotic process
Process	GO:0043067	Regulation of programmed cell death
Process	GO:0043170	Macromolecule metabolic process
Process	GO:0043368	Positive T cell selection
Process	GO:0043383	Negative T cell selection
Process	GO:0043412	Macromolecule modification
Process	GO:0043933	Protein-containing complex organization
Process	GO:0044085	Cellular component biogenesis
Process	GO:0044237	Cellular metabolic process
Process	GO:0044238	Primary metabolic process
Process	GO:0045058	T cell selection
Process	GO:0045059	Positive thymic T cell selection
Process	GO:0045060	Negative thymic T cell selection
Process	GO:0045061	Thymic T cell selection
Process	GO:0045321	Leukocyte activation
Process	GO:0045785	Positive regulation of cell adhesion
Process	GO:0045879	Negative regulation of smoothened signaling pathway
Process	GO:0045937	Positive regulation of phosphate metabolic process
Process	GO:0046629	Gamma-delta T cell activation
Process	GO:0046631	Alpha-beta T cell activation
Process	GO:0046633	Alpha-beta T cell proliferation
Process	GO:0046634	Regulation of alpha-beta T cell activation
Process	GO:0046635	Positive regulation of alpha-beta T cell activation
Process	GO:0046640	Regulation of alpha-beta T cell proliferation
Process	GO:0046641	Positive regulation of alpha-beta T cell proliferation
Process	GO:0046649	Lymphocyte activation
Process	GO:0046651	Lymphocyte proliferation
Process	GO:0048468	Cell development
Process	GO:0048513	Animal organ development
Process	GO:0048518	Positive regulation of biological process
Process	GO:0048519	Negative regulation of biological process
Process	GO:0048522	Positive regulation of cellular process
Process	GO:0048523	Negative regulation of cellular process
Process	GO:0048534	Hematopoietic or lymphoid organ development
Process	GO:0048583	Regulation of response to stimulus
Process	GO:0048584	Positive regulation of response to stimulus
Process	GO:0048585	Negative regulation of response to stimulus
Process	GO:0048666	Neuron development
Process	GO:0048699	Generation of neurons
Process	GO:0048731	System development
Process	GO:0048856	Anatomical structure development
Process	GO:0048869	Cellular developmental process
Process	GO:0050670	Regulation of lymphocyte proliferation
Process	GO:0050671	Positive regulation of lymphocyte proliferation
Process	GO:0050730	Regulation of peptidyl-tyrosine phosphorylation
Process	GO:0050731	Positive regulation of peptidyl-tyrosine phosphorylation
Process	GO:0050776	Regulation of immune response
Process	GO:0050778	Positive regulation of immune response
Process	GO:0050789	Regulation of biological process
Process	GO:0050794	Regulation of cellular process
Process	GO:0050848	Regulation of calcium-mediated signaling
Process	GO:0050850	Positive regulation of calcium-mediated signaling
Process	GO:0050851	Antigen receptor-mediated signaling pathway
Process	GO:0050852	T cell receptor signaling pathway
Process	GO:0050863	Regulation of T cell activation
Process	GO:0050865	Regulation of cell activation
Process	GO:0050867	Positive regulation of cell activation
Process	GO:0050870	Positive regulation of T cell activation
Process	GO:0050896	Response to stimulus
Process	GO:0051171	Regulation of nitrogen compound metabolic process
Process	GO:0051173	Positive regulation of nitrogen compound metabolic process
Process	GO:0051174	Regulation of phosphorus metabolic process
Process	GO:0051239	Regulation of multicellular organismal process
Process	GO:0051240	Positive regulation of multicellular organismal process
Process	GO:0051246	Regulation of protein metabolic process
Process	GO:0051247	Positive regulation of protein metabolic process
Process	GO:0051249	Regulation of lymphocyte activation
Process	GO:0051251	Positive regulation of lymphocyte activation
Process	GO:0051716	Cellular response to stimulus
Process	GO:0060255	Regulation of macromolecule metabolic process
Process	GO:0060322	Head development
Process	GO:0065003	Protein-containing complex assembly
Process	GO:0065007	Biological regulation
Process	GO:0070661	Leukocyte proliferation
Process	GO:0070663	Regulation of leukocyte proliferation
Process	GO:0070665	Positive regulation of leukocyte proliferation
Process	GO:0071704	Organic substance metabolic process
Process	GO:0071840	Cellular component organization or biogenesis
Process	GO:0080090	Regulation of primary metabolic process
Process	GO:0097190	Apoptotic signaling pathway
Process	GO:0120036	Plasma membrane bounded cell projection organization
Process	GO:1901564	Organonitrogen compound metabolic process
Process	GO:1902531	Regulation of intracellular signal transduction
Process	GO:1902533	Positive regulation of intracellular signal transduction
Process	GO:1903037	Regulation of leukocyte cell-cell adhesion
Process	GO:1903039	Positive regulation of leukocyte cell-cell adhesion
Process	GO:1903131	Mononuclear cell differentiation
Process	GO:2000514	Regulation of CD4-positive, alpha-beta T cell activation
Process	GO:2000516	Positive regulation of CD4-positive, alpha-beta T cell activation
Process	GO:2000561	Regulation of CD4-positive, alpha-beta T cell proliferation
Process	GO:2000563	Positive regulation of CD4-positive, alpha-beta T cell proliferation
Component	GO:0001772	Immunological synapse
Component	GO:0005622	Intracellular anatomical structure
Component	GO:0005737	Cytoplasm
Component	GO:0005783	Endoplasmic reticulum
Component	GO:0005794	Golgi apparatus
Component	GO:0005886	Plasma membrane
Component	GO:0005887	Integral component of plasma membrane
Component	GO:0005911	Cell-cell junction
Component	GO:0009897	External side of plasma membrane
Component	GO:0009986	Cell surface
Component	GO:0012505	Endomembrane system
Component	GO:0016020	Membrane
Component	GO:0016021	Integral component of membrane
Component	GO:0030054	Cell junction
Component	GO:0030425	Dendrite
Component	GO:0031224	Intrinsic component of membrane
Component	GO:0031226	Intrinsic component of plasma membrane
Component	GO:0032991	Protein-containing complex
Component	GO:0036477	Somatodendritic compartment
Component	GO:0042101	T cell receptor complex
Component	GO:0042105	Alpha-beta T cell receptor complex
Component	GO:0042106	Gamma-delta T cell receptor complex
Component	GO:0042995	Cell projection
Component	GO:0043005	Neuron projection
Component	GO:0043197	Dendritic spine
Component	GO:0043226	Organelle
Component	GO:0043227	Membrane-bounded organelle
Component	GO:0043229	Intracellular organelle
Component	GO:0043231	Intracellular membrane-bounded organelle
Component	GO:0043235	Receptor complex
Component	GO:0044297	Cell body
Component	GO:0044309	Neuron spine
Component	GO:0045202	Synapse
Component	GO:0070161	Anchoring junction
Component	GO:0071944	Cell periphery
Component	GO:0097447	Dendritic tree
Component	GO:0098552	Side of membrane
Component	GO:0098794	Postsynapse
Component	GO:0098796	Membrane protein complex
Component	GO:0098797	Plasma membrane protein complex
Component	GO:0098802	Plasma membrane signaling receptor complex
Component	GO:0110165	Cellular anatomical entity
Component	GO:0120025	Plasma membrane bounded cell projection
Function	GO:0004888	Transmembrane signaling receptor activity
Function	GO:0005102	Signaling receptor binding
Function	GO:0005488	Binding
Function	GO:0005515	Protein binding
Function	GO:0017124	SH3 domain binding
Function	GO:0019899	Enzyme binding
Function	GO:0019900	Kinase binding
Function	GO:0019901	Protein kinase binding
Function	GO:0019904	Protein domain specific binding
Function	GO:0030159	Signaling receptor complex adaptor activity
Function	GO:0030674	Protein-macromolecule adaptor activity
Function	GO:0035591	Signaling adaptor activity
Function	GO:0038023	Signaling receptor activity
Function	GO:0042608	T cell receptor binding
Function	GO:0042802	Identical protein binding
Function	GO:0044877	Protein-containing complex binding
Function	GO:0060089	Molecular transducer activity
Function	GO:0060090	Molecular adaptor activity

Pathway annotation

Category	Term ID	Term description
RCTM	HSA-1280218	Adaptive Immune System
RCTM	HSA-168256	Immune System
RCTM	HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
RCTM	HSA-202403	TCR signaling
RCTM	HSA-202424	Downstream TCR signaling
RCTM	HSA-202427	Phosphorylation of CD3 and TCR zeta chains
RCTM	HSA-202430	Translocation of ZAP-70 to Immunological synapse
RCTM	HSA-202433	Generation of second messenger molecules
RCTM	HSA-388841	Costimulation by the CD28 family
RCTM	HSA-389948	PD-1 signaling
WikiPathways	WP4585	Cancer immunotherapy by PD-1 blockade
WikiPathways	WP4630	Measles virus infection
WikiPathways	WP4884	Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex
WikiPathways	WP5055	Burn wound healing
WikiPathways	WP5072	Modulators of TCR signaling and T cell activation
WikiPathways	WP5098	T-cell activation SARS-CoV-2
WikiPathways	WP5115	Network map of SARS-CoV-2 signaling pathway
WikiPathways	WP5130	Th17 cell differentiation pathway
WikiPathways	WP69	T-cell receptor signaling pathway

Expression profile of CD3E in omics data

ID	GSE120596
Title	Variability in the Analgesic Response to Ibuprofen Following Third Molar Extraction is Associated with Differences in Activation of the Cyclooxygenase Pathway
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM3405450	1001_baseline	cell type: peripheral blood mononuclear cell subject: 1001 gender: Female timepoint: baseline library barcode: ATTACTCG-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder	1782.0
GSM3405451	1001_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1001 gender: Female timepoint: post-surgery 1 library barcode: TCCGGAGA-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder	867.0
GSM3405452	1002_baseline	cell type: peripheral blood mononuclear cell subject: 1002 gender: Female timepoint: baseline library barcode: CGCTCATT-TATAGCCT drug treatment: Placebo response group: Placebo	1568.0
GSM3405453	1002_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1002 gender: Female timepoint: post-surgery 1 library barcode: GAGATTCC-TATAGCCT drug treatment: Placebo response group: Placebo	924.0
GSM3405454	1003_baseline	cell type: peripheral blood mononuclear cell subject: 1003 gender: Male timepoint: baseline library barcode: ATTCAGAA-TATAGCCT drug treatment: ibuprofen sodium response group: Full responder	2564.0
GSM3405455	1003_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1003 gender: Male timepoint: post-surgery 1 library barcode: GAATTCGT-TATAGCCT drug treatment: ibuprofen sodium response group: Full responder	2365.0
GSM3405456	1004_baseline	cell type: peripheral blood mononuclear cell subject: 1004 gender: Male timepoint: baseline library barcode: CTGAAGCT-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder	2393.0
GSM3405457	1004_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1004 gender: Male timepoint: post-surgery 1 library barcode: TAATGCGC-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder
GSM3405458	1005_baseline	cell type: peripheral blood mononuclear cell subject: 1005 gender: Male timepoint: baseline library barcode: CGGCTATG-TATAGCCT drug treatment: Placebo response group: Placebo	2818.0
GSM3405459	1005_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1005 gender: Male timepoint: post-surgery 1 library barcode: TCCGCGAA-TATAGCCT drug treatment: Placebo response group: Placebo
GSM3405460	1006_baseline	cell type: peripheral blood mononuclear cell subject: 1006 gender: Male timepoint: baseline library barcode: TCTCGCGC-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder	1685.0
GSM3405461	1006_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1006 gender: Male timepoint: post-surgery 1 library barcode: AGCGATAG-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder	1337.0
GSM3405462	1007_baseline	cell type: peripheral blood mononuclear cell subject: 1007 gender: Male timepoint: baseline library barcode: ATTACTCG-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405463	1007_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1007 gender: Male timepoint: post-surgery 1 library barcode: TCCGGAGA-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405464	1008_baseline	cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: baseline library barcode: CGCTCATT-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405465	1008_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405466	1008_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405467	1011_baseline	cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: baseline library barcode: GAATTCGT-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder	1013.0
GSM3405468	1011_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405469	1011_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405470	1012_baseline	cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: baseline library barcode: CGGCTATG-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder	1811.0
GSM3405471	1012_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder	1890.0
GSM3405472	1012_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder
GSM3405473	1014_baseline	cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: baseline library barcode: AGCGATAG-ATAGAGGC drug treatment: Placebo response group: Placebo	1618.0
GSM3405474	1014_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: post-surgery 1 library barcode: ATTACTCG-CCTATCCT drug treatment: Placebo response group: Placebo	1424.0
GSM3405475	1014_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: post-surgery 2 library barcode: TCCGGAGA-CCTATCCT drug treatment: Placebo response group: Placebo	785.0
GSM3405476	1015_baseline	cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: baseline library barcode: CGCTCATT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder	1786.0
GSM3405477	1015_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder	1870.0
GSM3405478	1015_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder	1435.0
GSM3405479	1016_baseline	cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: baseline library barcode: GAATTCGT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder	2811.0
GSM3405480	1016_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: post-surgery 1 library barcode: CTGAAGCT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder	1939.0
GSM3405481	1016_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: post-surgery 2 library barcode: TAATGCGC-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder	2175.0
GSM3405482	1017_baseline	cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: baseline library barcode: CGGCTATG-CCTATCCT drug treatment: Placebo response group: Placebo	1548.0
GSM3405483	1017_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: post-surgery 1 library barcode: TCCGCGAA-CCTATCCT drug treatment: Placebo response group: Placebo	1587.0
GSM3405484	1017_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: post-surgery 2 library barcode: TCTCGCGC-CCTATCCT drug treatment: Placebo response group: Placebo	1558.0
GSM3405485	1018_baseline	cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: baseline library barcode: AGCGATAG-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder	2554.0
GSM3405486	1018_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder	2948.0
GSM3405487	1018_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder	2361.0
GSM3405488	1019_baseline	cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: baseline library barcode: CGCTCATT-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder	2807.0
GSM3405489	1019_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder	2643.0
GSM3405490	1019_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder	1530.0
GSM3405491	1020_baseline	cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: baseline library barcode: GAATTCGT-GGCTCTGA drug treatment: Placebo response group: Placebo
GSM3405492	1020_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-GGCTCTGA drug treatment: Placebo response group: Placebo	1675.0
GSM3405493	1020_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-GGCTCTGA drug treatment: Placebo response group: Placebo	976.0
GSM3405494	1021_baseline	cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: baseline library barcode: CGGCTATG-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder	1691.0
GSM3405495	1021_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder	1071.0
GSM3405496	1021_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder	916.0
GSM3405497	1022_baseline	cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: baseline library barcode: AGCGATAG-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder	2538.0
GSM3405498	1022_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: post-surgery 1 library barcode: ATTACTCG-AGGCGAAG drug treatment: ibuprofen sodium response group: Full responder	1266.0
GSM3405499	1022_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: post-surgery 2 library barcode: TCCGGAGA-AGGCGAAG drug treatment: ibuprofen sodium response group: Full responder	3041.0
GSM3405500	1023_baseline	cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: baseline library barcode: CGCTCATT-AGGCGAAG drug treatment: Placebo response group: Placebo	1638.0
GSM3405501	1023_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-AGGCGAAG drug treatment: Placebo response group: Placebo	1258.0
GSM3405502	1023_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-AGGCGAAG drug treatment: Placebo response group: Placebo	780.0
GSM3405503	1024_baseline	cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: baseline library barcode: GAATTCGT-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder	2273.0
GSM3405504	1024_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder	2762.0
GSM3405505	1024_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder	2274.0
GSM3405506	1026_baseline	cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: baseline library barcode: CGGCTATG-AGGCGAAG drug treatment: Placebo response group: Placebo	1963.0
GSM3405507	1026_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-AGGCGAAG drug treatment: Placebo response group: Placebo	1708.0
GSM3405508	1026_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-AGGCGAAG drug treatment: Placebo response group: Placebo	1571.0
GSM3405509	1027_baseline	cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: baseline library barcode: AGCGATAG-AGGCGAAG drug treatment: Placebo response group: Placebo	1857.0
GSM3405510	1027_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-TAATCTTA drug treatment: Placebo response group: Placebo	1719.0
GSM3405511	1027_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-TAATCTTA drug treatment: Placebo response group: Placebo	1282.0
GSM3405512	1028_baseline	cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: baseline library barcode: CGCTCATT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	2077.0
GSM3405513	1028_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	2016.0
GSM3405514	1028_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	1663.0
GSM3405515	1029_baseline	cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: baseline library barcode: GAATTCGT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	925.0
GSM3405516	1029_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: post-surgery 1 library barcode: CTGAAGCT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	964.0
GSM3405517	1029_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: post-surgery 2 library barcode: TAATGCGC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	978.0
GSM3405518	1030_baseline	cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: baseline library barcode: CGGCTATG-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	1718.0
GSM3405519	1030_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	1689.0
GSM3405520	1030_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder	1635.0
GSM3405521	1032_baseline	cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: baseline library barcode: AGCGATAG-TAATCTTA drug treatment: Placebo response group: Placebo	2692.0
GSM3405522	1032_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-CAGGACGT drug treatment: Placebo response group: Placebo	3110.0
GSM3405523	1032_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-CAGGACGT drug treatment: Placebo response group: Placebo	2513.0
GSM3405524	1033_baseline	cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: baseline library barcode: CGCTCATT-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder	1658.0
GSM3405525	1033_post-surgery_1	cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder	2200.0
GSM3405526	1033_post-surgery_2	cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder	2029.0

ID	GSE12860
Title	Antirheumatic Drug Response in Human Chondrocytes: Potential Molecular Targets to Stimulate Cartilage Regeneration
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM322609	RASF stimulated chondrocytes rep 1 GSM253283	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium	6.775040161
GSM322610	RASF stimulated chondrocytes rep 2 GSM253284	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium	6.362024788
GSM322611	NDSF stimulated chondrocytes rep 1 GSM253285	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of NDSF cultured in the same medium	6.453215145
GSM322612	NDSF stimulated chondrocytes rep 2 GSM253286	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of NDSF cultured in the same medium	6.349652111
GSM322613	Chondrocytes stimulated with diclofenac treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with diclofenac for 48h	6.77021729
GSM322614	Chondrocytes stimulated with diclofenac treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with diclofenac for 48h	6.754762999
GSM322615	Chondrocytes stimulated with prioxicam treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with piroxicam for 48h	6.876174827
GSM322616	Chondrocytes stimulated with prioxicam treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with piroxicam for 48h	6.437029087
GSM322617	Chondrocytes stimulated with chloroquine phosphate (resochin) treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with chloroquine phosphate (resochin) for 48h	6.767752091
GSM322618	Chondrocytes stimulated with chloroquine phosphate (resochin) treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with chloroquine phosphate (resochin) for 48h	6.431278279
GSM322619	Chondrocytes stimulated with sodium aurothiomalate (tauredon) treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with sodium aurothiomalate (tauredon) for 48h	6.904919773
GSM322620	Chondrocytes stimulated with sodium aurothiomalate (tauredon) treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with sodium aurothiomalate (tauredon) for 48h	7.059592195
GSM322621	Chondrocytes stimulated with azathioprine (imurek) treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with azathioprine (imurek) for 48h	6.761050462
GSM322622	Chondrocytes stimulated with azathioprine (imurek) treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with azathioprine (imurek) for 48h	6.679882374
GSM322623	Chondrocytes stimulated with methotrexate treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methotrexate for 48h	6.992746656
GSM322624	Chondrocytes stimulated with methotrexate treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methotrexate for 48h	6.839808448
GSM322625	Chondrocytes stimulated with prednisolone (solu-decortin) treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with prednisolone (solu-decortin) for 48h	6.905004813
GSM322626	Chondrocytes stimulated with prednisolone (solu-decortin) treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with prednisolone (solu-decortin) for 48h	6.88857732
GSM322627	Chondrocytes stimulated with methylprednisolone (urbason) treated RASF rep 1	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methylprednisolone (urbason) for 48h	6.709798746
GSM322628	Chondrocytes stimulated with methylprednisolone (urbason) treated RASF rep 2	Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methylprednisolone (urbason) for 48h	6.593863541

ID	GSE150408
Title	Identification of key genes potentially related to intervertebral disc degeneration by microarray analysis
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM4548691	volunteer-9	tissue: whole blood diagnosis: healthy control treatment: n/a	7.09720602
GSM4548692	volunteer-10	tissue: whole blood diagnosis: healthy control treatment: n/a	6.833574265
GSM4548693	volunteer-11	tissue: whole blood diagnosis: healthy control treatment: n/a	6.413529314
GSM4548694	volunteer-12	tissue: whole blood diagnosis: healthy control treatment: n/a	7.255256541
GSM4548695	volunteer-13	tissue: whole blood diagnosis: healthy control treatment: n/a	6.926395066
GSM4548696	volunteer-14	tissue: whole blood diagnosis: healthy control treatment: n/a	7.208463409
GSM4548697	volunteer-15	tissue: whole blood diagnosis: healthy control treatment: n/a	6.941557227
GSM4548698	volunteer-16	tissue: whole blood diagnosis: healthy control treatment: n/a	7.076723461
GSM4548699	volunteer-17	tissue: whole blood diagnosis: healthy control treatment: n/a	6.600416793
GSM4548700	volunteer-18	tissue: whole blood diagnosis: healthy control treatment: n/a	6.68489424
GSM4548701	volunteer-19	tissue: whole blood diagnosis: healthy control treatment: n/a	6.9158457
GSM4548702	volunteer-20	tissue: whole blood diagnosis: healthy control treatment: n/a	6.475488537
GSM4548703	volunteer-21	tissue: whole blood diagnosis: healthy control treatment: n/a	6.531975003
GSM4548704	volunteer-22	tissue: whole blood diagnosis: healthy control treatment: n/a	8.280001288
GSM4548705	volunteer-23	tissue: whole blood diagnosis: healthy control treatment: n/a	8.07829399
GSM4548706	volunteer-24	tissue: whole blood diagnosis: healthy control treatment: n/a	8.04929317
GSM4548707	volunteer-25	tissue: whole blood diagnosis: healthy control treatment: n/a	8.288241612
GSM4548708	patient-9	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	6.284403062
GSM4548709	patient-10	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	7.071470683
GSM4548710	patient-11	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	6.545716542
GSM4548711	patient-12	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	7.024503399
GSM4548712	patient-13	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	6.597922264
GSM4548713	patient-14	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	6.903728231
GSM4548714	patient-15	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	6.983647339
GSM4548715	patient-16	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	6.585194902
GSM4548716	patient-17	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	7.363129976
GSM4548717	patient-18	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	7.451242156
GSM4548718	patient-19	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	6.980243596
GSM4548719	patient-20	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	6.628669986
GSM4548720	patient-21	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	8.394995914
GSM4548721	patient-22	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	8.823678103
GSM4548722	patient-23	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	8.368052294
GSM4548723	patient-24	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	8.000760503
GSM4548724	patient-25	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none	8.352624096
GSM4548725	treatment-1	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	6.541532229
GSM4548726	treatment-2	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.120809461
GSM4548727	treatment-3	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	6.882251591
GSM4548728	treatment-4	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	6.847888989
GSM4548729	treatment-5	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	6.472274066
GSM4548730	treatment-6	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	6.750140809
GSM4548731	treatment-7	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	6.578601069
GSM4548732	treatment-8	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	6.485438066
GSM4548733	treatment-9	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	6.544654031
GSM4548734	treatment-10	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	6.762929647
GSM4548735	treatment-11	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	6.781520977
GSM4548736	treatment-12	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	6.488172583
GSM4548737	treatment-13	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.784471614
GSM4548738	treatment-14	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.892262469
GSM4548739	treatment-15	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.805989964
GSM4548740	treatment-16	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.054032817
GSM4548741	treatment-17	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.823991326
GSM4548742	treatment-18	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	8.197915585
GSM4548743	treatment-19	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.327050627
GSM4548744	treatment-20	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.047647507
GSM4548745	treatment-21	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.556766549
GSM4548746	treatment-22	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.198521148
GSM4548747	treatment-23	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	6.489571082
GSM4548748	treatment-24	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.017274355
GSM4548749	treatment-25	tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine	7.056934325

ID	GSE179004
Title	Expression data from glioblastoma surgical specimens
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM5403447	glioblastoma tissue 1 in TIVA group	tissue: glioblastoma	5.983187414
GSM5403448	glioblastoma tissue 2 in TIVA group	tissue: glioblastoma	3.595880795
GSM5403449	glioblastoma tissue 3 in TIVA group	tissue: glioblastoma	3.159631852
GSM5403450	glioblastoma tissue 1 in INHA group	tissue: glioblastoma	3.942832759
GSM5403451	glioblastoma tissue 2 in INHA group	tissue: glioblastoma	3.265526611
GSM5403452	glioblastoma tissue 3 in INHA group	tissue: glioblastoma	3.836865866

ID	GSE212044
Title	Reversibility of etomidate-induced contractile arrest through activation of myocardial autophagy
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM6508421	IPSC-CM cells, DSMO 1	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30	0.0
GSM6508422	IPSC-CM cells, DSMO 2	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30	0.0
GSM6508423	IPSC-CM cells, DSMO 3	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30	0.0
GSM6508424	IPSC-CM cells, Etomidate 1	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30	0.0
GSM6508425	IPSC-CM cells, Etomidate 2	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30	0.0
GSM6508426	IPSC-CM cells, Etomidate 3	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30	0.0
GSM6508427	IPSC-CM cells, Propofol 1	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30	0.0
GSM6508428	IPSC-CM cells, Propofol 2	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30	1.0
GSM6508429	IPSC-CM cells, Propofol 3	cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30	0.0

ID	GSE255952
Title	Transcriptome data of B cells and T helper cells from patients with multiple sclerosis receiving methylprednisolone for the treatment of an acute relapse
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM8083291	patient C1P1, before first course of MP, T cells	tissue: peripheral blood patient id: C1P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 34.9 cells per ml: 2982000 purity (%): 98.1 rna integrity number: 7.8 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss	18.35956
GSM8083292	patient C1P1, after first course of MP, T cells	tissue: peripheral blood patient id: C1P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 25.9 cells per ml: 304500 purity (%): 95.3 rna integrity number: 8.7 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss	17.73425
GSM8083293	patient C1P1, before second course of MP, T cells	tissue: peripheral blood patient id: C1P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.8 cells per ml: 1254750 purity (%): 96.7 rna integrity number: 8.3 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea	18.34459
GSM8083294	patient C1P1, after second course of MP, T cells	tissue: peripheral blood patient id: C1P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.6 cells per ml: 231000 purity (%): 93.7 rna integrity number: 9.4 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea	17.71589
GSM8083295	patient C1P2, before first course of MP, B cells	tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 4.7 cells per ml: 236250 purity (%): 91.9 rna integrity number: 9.0 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none	7.10356
GSM8083296	patient C1P2, after first course of MP, B cells	tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 3.7 cells per ml: 283500 purity (%): 91.0 rna integrity number: 9.1 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none	5.6289
GSM8083297	patient C1P2, before first course of MP, T cells	tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 28.7 cells per ml: 693000 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none	17.96269
GSM8083298	patient C1P2, after first course of MP, T cells	tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.5 cells per ml: 624750 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none	17.76352
GSM8083299	patient C1P3, before first course of MP, B cells	tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 10.0 cells per ml: 498750 purity (%): 98.8 rna integrity number: 8.9 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	6.25642
GSM8083300	patient C1P3, after first course of MP, B cells	tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.7 cells per ml: 383250 purity (%): 97.9 rna integrity number: 9.4 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	4.96218
GSM8083301	patient C1P3, before first course of MP, T cells	tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 31.0 cells per ml: 1134000 purity (%): 94.7 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	18.01726
GSM8083302	patient C1P3, after first course of MP, T cells	tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 18.1 cells per ml: 640500 purity (%): 96.2 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	17.96982
GSM8083303	patient C1P3, before second course of MP, T cells	tissue: peripheral blood patient id: C1P3 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 30.3 cells per ml: 897750 purity (%): 97.0 rna integrity number: 8.5 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp	18.07611
GSM8083304	patient C1P3, after second course of MP, T cells	tissue: peripheral blood patient id: C1P3 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.7 cells per ml: 1433250 purity (%): 97.5 rna integrity number: 8.3 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 5 side effects to mp: none	18.23381
GSM8083305	patient C1P4, before first course of MP, B cells	tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.3 cells per ml: 378000 purity (%): 96.3 rna integrity number: 9.6 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	7.0161
GSM8083306	patient C1P4, after first course of MP, B cells	tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.5 cells per ml: 939750 purity (%): 96.7 rna integrity number: 8.8 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	6.12464
GSM8083307	patient C1P4, before first course of MP, T cells	tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 38.1 cells per ml: 1522500 purity (%): 98.7 rna integrity number: NA age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	17.89398
GSM8083308	patient C1P4, after first course of MP, T cells	tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 15.9 cells per ml: 1617000 purity (%): 98.3 rna integrity number: 8.5 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	17.97076
GSM8083309	patient C1P5, before first course of MP, T cells	tissue: peripheral blood patient id: C1P5 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 31.6 cells per ml: 1344000 purity (%): 99.1 rna integrity number: 8.0 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none	18.23588
GSM8083310	patient C1P5, after first course of MP, T cells	tissue: peripheral blood patient id: C1P5 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 21.9 cells per ml: 1165500 purity (%): 98.9 rna integrity number: 8.4 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none	17.93802
GSM8083311	patient C1P5, before second course of MP, T cells	tissue: peripheral blood patient id: C1P5 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 26.9 cells per ml: 1233750 purity (%): 97.8 rna integrity number: 8.5 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems	18.31241
GSM8083312	patient C1P5, after second course of MP, T cells	tissue: peripheral blood patient id: C1P5 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.0 cells per ml: 514500 purity (%): 98.6 rna integrity number: 8.7 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems	17.51941
GSM8083313	patient C2P1, before first course of MP, B cells	tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 11.7 cells per ml: 2604000 purity (%): 96.7 rna integrity number: 8.5 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	7.24253
GSM8083314	patient C2P1, after first course of MP, B cells	tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 8.8 cells per ml: 630000 purity (%): 97.4 rna integrity number: 8.4 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	5.33286
GSM8083315	patient C2P1, before first course of MP, T cells	tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 41.5 cells per ml: 2436000 purity (%): 94.6 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	18.32407
GSM8083316	patient C2P1, after first course of MP, T cells	tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.2 cells per ml: 346500 purity (%): 86.5 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	16.27422
GSM8083317	patient C2P2, before first course of MP, B cells	tissue: peripheral blood patient id: C2P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.9 cells per ml: 467250 purity (%): 87.3 rna integrity number: 8.8 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	6.91625
GSM8083318	patient C2P2, after first course of MP, B cells	tissue: peripheral blood patient id: C2P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.3 cells per ml: 199500 purity (%): 97.6 rna integrity number: 9.5 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: 1.5 disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	5.90032
GSM8083319	patient C2P3, before first course of MP, B cells	tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	6.33294
GSM8083320	patient C2P3, after first course of MP, B cells	tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	4.9861
GSM8083321	patient C2P3, before first course of MP, T cells	tissue: peripheral blood patient id: C2P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 20.2 cells per ml: 1711500 purity (%): 94.3 rna integrity number: 7.3 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	18.35683
GSM8083322	patient C2P3, after first course of MP, T cells	tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 22.8 cells per ml: 992250 purity (%): 96.5 rna integrity number: 8.2 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	15.75193
GSM8083323	patient C2P4, before first course of MP, B cells	tissue: peripheral blood patient id: C2P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 8.0 cells per ml: 1690500 purity (%): 96.3 rna integrity number: 9.0 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	6.15868
GSM8083324	patient C2P4, after first course of MP, B cells	tissue: peripheral blood patient id: C2P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 2.2 cells per ml: 273000 purity (%): 93.0 rna integrity number: 8.3 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	4.76011
GSM8083325	patient C2P5, before first course of MP, B cells	tissue: peripheral blood patient id: C2P5 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.6 cells per ml: 136500 purity (%): 53.8 rna integrity number: 6.9 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	8.41222
GSM8083326	patient C2P5, after first course of MP, B cells	tissue: peripheral blood patient id: C2P5 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.8 cells per ml: 687750 purity (%): 98.1 rna integrity number: 8.2 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none	4.21489
GSM8083327	patient C2P6, before first course of MP, B cells	tissue: peripheral blood patient id: C2P6 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 4.2 cells per ml: 546000 purity (%): 92.4 rna integrity number: 8.8 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: 6.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	7.07596
GSM8083328	patient C2P6, after first course of MP, B cells	tissue: peripheral blood patient id: C2P6 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 6.6 cells per ml: 714000 purity (%): 97.8 rna integrity number: 9.0 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: NA disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	5.76329
GSM8083329	patient C2P7, before first course of MP, B cells	tissue: peripheral blood patient id: C2P7 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.7 cells per ml: 215250 purity (%): 95.6 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: yes fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none	6.80872
GSM8083330	patient C2P7, after first course of MP, B cells	tissue: peripheral blood patient id: C2P7 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.8 cells per ml: 162750 purity (%): 93.2 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: better fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none	4.82141
GSM8083331	patient C2P8, before first course of MP, B cells	tissue: peripheral blood patient id: C2P8 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 3.5 cells per ml: 220500 purity (%): 95.5 rna integrity number: 8.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	4.07635
GSM8083332	patient C2P8, after first course of MP, B cells	tissue: peripheral blood patient id: C2P8 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 11.0 cells per ml: 535500 purity (%): 97.3 rna integrity number: 7.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none	4.2612
GSM8083333	patient C3P1, before second course of MP, T cells	tissue: peripheral blood patient id: C3P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 24.0 cells per ml: 225750 purity (%): 97.0 rna integrity number: 7.9 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: yes total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none	17.39178
GSM8083334	patient C3P1, after second course of MP, T cells	tissue: peripheral blood patient id: C3P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 10.1 cells per ml: 315000 purity (%): 98.6 rna integrity number: 8.3 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: worse total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none	17.68375
GSM8083335	patient C4P1, before first course of MP, B cells	tissue: peripheral blood patient id: C4P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 5.3 cells per ml: 336000 purity (%): 96.3 rna integrity number: 9.4 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis	4.44039
GSM8083336	patient C4P1, after first course of MP, B cells	tissue: peripheral blood patient id: C4P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.9 cells per ml: 1417500 purity (%): 96.1 rna integrity number: 8.7 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis	5.29313
GSM8083337	patient C4P2, before first course of MP, B cells	tissue: peripheral blood patient id: C4P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: NA cells per ml: 493500 purity (%): 94.2 rna integrity number: 8.2 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 7.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: yes fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none	5.2983
GSM8083338	patient C4P2, after first course of MP, B cells	tissue: peripheral blood patient id: C4P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.4 cells per ml: 236250 purity (%): 42.7 rna integrity number: 8.1 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 6.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none	5.12781

ID	GSE4386
Title	Transcriptomics in cardiac surgery
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM99229	H01_S_B1	male CABG patient, atrial tissue baseline before CABG surgery	3.161547594
GSM99235	H01_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	3.172053573
GSM99239	H02_P_B1	male CABG patient, atrial tissue baseline before CABG surgery	3.152931062
GSM99241	H02_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	3.176035522
GSM99244	H03_P_B1	male CABG patient, atrial tissue baseline before CABG surgery	3.170637078
GSM99246	H03_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	3.174809613
GSM99247	H04_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.16258256
GSM99249	H04_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	3.160287234
GSM99252	H05_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.149289216
GSM99253	H05_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	3.75690195
GSM99255	H06_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.192239069
GSM99257	H06_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	3.174926866
GSM99258	H07_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.162303864
GSM99259	H07_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	3.161775111
GSM99261	H08_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.121973008
GSM99265	H08_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	3.158852705
GSM99268	H09_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.138296527
GSM99271	H09_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	3.136805025
GSM99274	H10_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.233871775
GSM99277	H10_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	3.208873138
GSM99280	H11_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.097311391
GSM99282	H11_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	3.146243727
GSM99285	H12_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.189773853
GSM99287	H12_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	3.201025423
GSM99289	H13_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.140705155
GSM99290	H13_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	3.196827124
GSM99291	H14_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.174560571
GSM99292	H14_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	3.181265358
GSM99293	H15_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.165695467
GSM99294	H15_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	3.218237076
GSM99295	H16_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.18908552
GSM99296	H16_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	3.209881838
GSM99298	H17_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.160249292
GSM99299	H17_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	3.158097292
GSM99301	H18_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.194909277
GSM99302	H18_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	3.182819957
GSM99303	H19_P_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.136486585
GSM99304	H19_P_B2	male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery	3.170446065
GSM99305	H20_S_B1	male CABG patient, atrial tissue, baseline before CABG surgery	3.137803449
GSM99306	H20_S_B2	male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery	3.156601829

ID	GSE56256
Title	Influence of hexafluoro-2-propanol (HFIP) on lipopolysaccharides-induced inflammation in human microvascular endothelial cells of the lung
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM1357752	7_HFIP	cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs	14.22889
GSM1357753	8_HFIP	cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs	38.65361
GSM1357754	9_HFIP	cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs	8.048432
GSM1357755	4_LPS	cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs	5.6746165
GSM1357756	5_LPS	cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs	197.20344999999998
GSM1357757	6_LPS	cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs	5.773757
GSM1357758	11_LPS-HFIP	cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL and HFIP 8mmol/L over a time period of 6 hrs	5.850098
GSM1357759	12_LPS-HFIP	cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL and HFIP 8mmol/L over a time period of 6 hrs	5.4933285000000005
GSM1357760	1_PBS	cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs	7.334543
GSM1357761	2_PBS	cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs	9.0099315
GSM1357762	3_PBS	cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs	11.7533295

ID	GSE59526
Title	Affymetrix Chip data of the transcriptome of human clinical study for acupuncture mechanisms on rheumatoid arthritis
Organism	Homo sapiens

GSM	Sample info	Characteristics	Value
GSM1438864	Peripheral blood mononuclear cells from AP group, Patient 2 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 53 treatment group: acupuncture+methotrexate time point: before therapy patient id: 2	124.8812646
GSM1438865	Peripheral blood mononuclear cells from AP group, Patient 3 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 48 treatment group: acupuncture+methotrexate time point: before therapy patient id: 3	196.3183534
GSM1438866	Peripheral blood mononuclear cells from AP group, Patient 6 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 36 treatment group: acupuncture+methotrexate time point: before therapy patient id: 6	161.8319285
GSM1438867	Peripheral blood mononuclear cells from AP group, Patient 8 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 60 treatment group: acupuncture+methotrexate time point: before therapy patient id: 8	160.8397172
GSM1438868	Peripheral blood mononuclear cells from AP group, Patient 9 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 31 treatment group: acupuncture+methotrexate time point: before therapy patient id: 9	125.7057372
GSM1438869	Peripheral blood mononuclear cells from MTX group, Patient 4 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 61 treatment group: methotrexate time point: before therapy patient id: 4	338.6600547
GSM1438870	Peripheral blood mononuclear cells from MTX group, Patient 5 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 49 treatment group: methotrexate time point: before therapy patient id: 5	178.0442756
GSM1438871	Peripheral blood mononuclear cells from MTX group, Patient 7 before therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 35 treatment group: methotrexate time point: before therapy patient id: 7	157.9975789
GSM1438872	Peripheral blood mononuclear cells from Patient 1 after 2 weeks acupuncture therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 64 treatment group: acupuncture+methotrexate time point: after 2 weeks therapy patient id: 1	143.8440729
GSM1438873	Peripheral blood mononuclear cells from Patient 3 after 2 weeks acupuncture therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 48 treatment group: acupuncture+methotrexate time point: after 2 weeks therapy patient id: 3	173.1347072
GSM1438874	Peripheral blood mononuclear cells from Patient 1 after 3 months acupuncture therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 64 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 1	193.2050839
GSM1438875	Peripheral blood mononuclear cells from Patient 2 after 3 months acupuncture therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 53 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 2	139.0125667
GSM1438876	Peripheral blood mononuclear cells from Patient 6 after 3 months acupuncture therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 36 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 6	161.2770264
GSM1438877	Peripheral blood mononuclear cells from Patient 8 after 3 months acupuncture therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 60 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id:	173.4201204
GSM1438878	Peripheral blood mononuclear cells from Patient 9 after 3 months acupuncture therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 31 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 9	179.7718131
GSM1438879	Peripheral blood mononuclear cells from Patient 4 after 3 months MTX therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 61 treatment group: methotrexate time point: after 3 months therapy patient id: 4	99.77385503
GSM1438880	Peripheral blood mononuclear cells from Patient 5 after 3 months MTX therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 49 treatment group: methotrexate time point: after 3 months therapy patient id: 5	147.6294275
GSM1438881	Peripheral blood mononuclear cells from Patient 7 after 3 months MTX therapy	cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 35 treatment group: methotrexate time point: after 3 months therapy patient id: 7	155.7842825